Comparison of the CytoSorb ® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study
Axel Nierhaus et al. Minim Invasive Ther Allied Technol. 2022.
Hide details
Minim Invasive Ther Allied Technol
. 2022 Aug 1;1-8.
doi: 10.1080/13645706.2022.2104617. Online ahead of print.
Authors
Axel Nierhaus 1 2 , Jesus Morales 3 , Daniel Wendt 3 4 , Jörg Scheier 3 , Dominik Gutzler 3 , Dominik Jarczak 1 2 , Frank Born 5 , Christian Hagl 5 , Efthymios Deliargyris 3 , Yatin Mehta 6
Affiliations
1 Clinic for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg, Hamburg, Germany.
2 Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
3 CytoSorbents, Princeton, NJ, USA.
4 Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen, Essen, Germany.
5 Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.
6 Medanta Institute of Critical Care and Anesthesiology, Gurgaon, India.
PMID: 35913784
DOI: 10.1080/13645706.2022.2104617
Cite
Abstract
Introduction: We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-a and monocyte chemoattractant protein (MCP)-1 from blood.
Material and methods: An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb® 300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFa and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).
Results: Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFa and MCP-1 were removed faster and to a higher extent by the CytoSorb® 300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb® 300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-a: 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).
Conclusions: Both the CytoSorb® and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb® 300 device was significantly more efficient achieving the bulk of the removal in the first 120 min.
